BRIEF-Arch Biopartners says European Commission designated AB569 as orphan medicinal product in EU

* European Commission designated AB569 as orphan medicinal product in European Union for treatment of patients with cystic fibrosis Source text for Eikon: Further company coverage:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.